CLS obtains first order for its diffusor fiber, for MRI-guided laser ablation, from a leading cancer clinic in the US
Clinical Laserthermia Systems (CLS) (publ), has received its first order for the company’s product TRANBERG®|Laser Applicator Non-cooled diffusor fiber for MRI-guided laser ablation. The purchase order comes from the same leading US hospital that earlier this year bought the TRANBERG® |Mobile Laser Unit.
The background to the purchase is the hospital’s extensive operations in the area of image-guided minimal invasive treatment of tumors. Together the parties are preparing for a collaboration in order to evaluate, and further develop, CLS proprietary immunostimulating treatment, imILT®, as well as MRI-guided laser ablation. This initial order holds a value of about 50 000 SEK.
TRANBERG®|Laser Applicator Non-cooled diffusor fiber allows treatment of larger cancer tumors and can be used for imILT® as well as for MRI-guided laser ablation.
“This order launches the collaboration in the US with a very important customer of ours. The hospital represents a solid and well-known brand in the US and abroad. The symbolic value is far greater and more important than the revenue from this initial order”, said Dan Mogren, CCO at CLS. “That a leading hospital choses CLS’ diffusor fiber builds trust for our products”, concludes Dan Mogren.
CLS develops and markets the TRANBERG®|Thermal Therapy System, as well as disposable materials and methods for heat-induced immunotherapy for safe and gentle treatment of cancerous tumors. The Company recently bought the part of the German laser technology company Laser- und Medizin-Technologie GmbH (LMTB), that includes technology and development of CLS diffusor fiber. The production of the fiber is based on unique expertise in micro-structuring of laser fiber, which is the formation of the structure that gives the light its unique diffusion.
Earlier this year CLS got an FDA-clearance for the TRANBERG®|Laser Applicator Non-cooled diffusor fiber, which means that the product is ready to be marketed in the US.
Lars-Erik Eriksson, CEO Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)702 – 90 33 00 E-mail: email@example.com
This information is such that Clinical Laserthermia Systems AB (publ) is required to publish pursuant to the EE Market Abuse Directive. The contact person arranged for the release of this information on 5 June 2017.
Lars-Erik Eriksson, CEO, Clinical Laserthermia Systems AB (publ)
Ph: +46 – (0)702 – 90 33 00 E-mail: firstname.lastname@example.org
Clinical Laserthermia Systems AB (publ), develops and sells the TRANBERG®|Thermal Therapy System and specially designed sterile disposable products for safe, gentle and effective treatment of cancerous tumors. The products are marketed for image-guided laser ablation and for treatment with immunostimulating interstitial laser thermotherapy, imILT®. The company, which is headquartered in Lund Sweden and has a subsidiary in Boston, MA, is listed Nasdaq First North under the ticker CLS B. Certified Adviser is Västra Hamnen Corporate Finance. Further information is available on the company’s websites: www.clinicallaser.se